Table 3

Unadjusted and Adjusted 3-Year Clinical Outcomes According to Coronary Artery Calcification Severity

Moderate or Severe CAC
(n = 1,622)
No or Mild CAC
(n = 4,749)
Univariate HR (95% CI)Adjusted HR (95% CI)Adjusted p Value
Co–primary composite endpoints
 Death, myocardial infarction, or target lesion revascularization(257) 18.2 (16.2–20.4)(544) 13.1 (12.1–14.2)1.65 (1.41–1.92)1.56 (1.33–1.84)<0.0001
 Death, myocardial infarction, or stent thrombosis(178) 12.7 (11.1–14.7)(354) 8.6 (7.8–9.5)1.72 (1.42–2.07)1.48 (1.21–1.80)0.0001
Non-stent-related adverse events
 Death(96) 5.9 (4.9–7.2)(194) 4.1 (3.6–4.7)1.82 (1.41–2.34)1.38 (1.05–1.81)0.02
 Cardiac death(54) 3.3 (2.6–4.3)(105) 2.2 (1.8–2.7)1.89 (1.34–2.67)1.44 (1.00–2.07)0.046
 Myocardial infarction(102) 6.3 (5.21–7.6)(182) 3.8 (3.3–4.4)1.76 (1.38–2.26)1.67 (1.28–2.18)0.0001
 Death or myocardial infarction(176) 10.9 (9.4–12.5)(349) 7.4 (6.6–8.1)1.72 (1.43–2.08)1.48 (1.21–1.81)0.0001
Stent-related adverse events
 Target lesion revascularization(108) 6.7 (5.6–7.9)(242) 5.1 (4.5–5.8)1.51 (1.19–1.91)1.63 (1.27–2.10)0.0001
 Definite or probable stent thrombosis(25) 1.5 (1.0–2.3)(42) 0.9 (0.7–1.2)1.73 (1.05–2.86)1.52 (0.89–2.59)0.13

Values are (number of events), Kaplan-Meier estimates (95% CI), and HR (95% CI). HRs are expressed with no or mild CAC as the reference group.

CAC = coronary artery calcification; CI = confidence interval; HR = hazard ratio.

  • Model adjusted for age, diabetes, body mass index, arterial hypertension, hypercholesterolemia, previous myocardial infarction, previous percutaneous coronary intervention, previous coronary artery bypass graft, family history of coronary artery disease, smoking, clinical presentation, multivessel disease, and number of stents implanted. Trial identifier included as a random effect in the multivariate model.

  • Wald p value.